Science and Research

Autoantibodies to IL-1Ra and PGRN in severe COVID-19 are associated with inflammation-induced hyperphosphorylated antigen isoforms

SARS-CoV-2 infection affects multiple immune mechanisms and leads to severe COVID-19 and death, in part related to infection-induced or pre-existing autoantibodies. Here, we describe severe COVID-19 to associate with autoantibodies against interleukin-1 receptor antagonist (IL-1Ra) and progranulin (PGRN), endogenous antagonists of IL-1 and TNF signaling, respectively. These autoantibodies coincide with hyperphosphorylation of IL-1Ra (Thr111) or PGRN (Ser81), form immune complexes independent of phosphorylation, reduce antigen plasma levels, and permit enhanced IL-1 and TNF signaling. Using phage-display selected Fabs specific for hyperphosphorylated isoforms, we track phospho-antigens and autoantibodies in a German national pandemic network cohort. Most seropositive patients show both autoantibodies. Levels peak at baseline and decline over 12 months, with phospho-antigens decreasing before autoantibodies. Seropositivity associates with hyperinflammation and cytokine profiles. Importantly, signaling by key inflammatory cytokines induce IL-1Ra and PGRN hyperphosphorylation in healthy monocytes, but require up to 1000-fold higher doses than in monocytes from previously seropositive severe COVID-19 survivors.

  • Thurner, L.
  • Fadle, N.
  • Thurner, B.
  • Kos, I. A.
  • Bewarder, M.
  • Regitz, E.
  • Bette, B.
  • Fischer, Y.
  • Lesan, V.
  • Rixecker, T.
  • Hoffmann, M. C.
  • Preuss, K. D.
  • Schormann, C.
  • Kaddu-Mulindwa, D.
  • Roemer, K.
  • Cetin, O.
  • Mang, S.
  • Becker, A.
  • Seiler, F.
  • Herr, C.
  • Lensch, C.
  • Lehmann, J.
  • Thiel-Bodenstaff, A.
  • Link, A.
  • Werner, C.
  • Wuchter, P.
  • Korper, S.
  • Pfuhl, T.
  • Lohse, S.
  • Rissland, J.
  • Thieser, K.
  • Pilch, J.
  • Papan, C.
  • Roth, S.
  • Vehreschild, J. J.
  • Scherer, M.
  • Brohl, I.
  • Wagner, P.
  • Witzenrath, M.
  • Thibeault, C.
  • Haack, I. A.
  • Mitrov, L.
  • Putz, S. M.
  • Reese, J. P.
  • Krawczak, M.
  • Hamelmann, E.
  • Kopfnagel, V.
  • Fiedler, K.
  • Geisler, R.
  • Valentin, H.
  • Stahl, D.
  • Hanss, S.
  • Ameling, S.
  • Volker, U.
  • Hansch, S.
  • Dorr, M.
  • Blaschke, S.
  • Braunsteiner, J.
  • Dahl, E.
  • Pape, D.
  • Petersmann, A.
  • Stilgenbauer, S.
  • Bloos, F.
  • Schrezenmeier, H.
  • Langer, F.
  • Gabelein, G.
  • Friesenhahn-Ochs, B.
  • Pfeifer, J.
  • Bauer, M.
  • Becker, S. L.
  • Neumann, F.
  • Bohm, M.
  • Anton, G.
  • Kuenne, C.
  • Pullamsetti, S. S.
  • Looso, M.
  • Bals, R.
  • Smola, S.
  • Meybohm, P.
  • Krawczyk, M.
  • Lepper, P. M.
  • Kessel, C.

Keywords

  • Humans
  • *COVID-19/immunology/virology
  • Phosphorylation
  • *Interleukin 1 Receptor Antagonist Protein/immunology
  • *Autoantibodies/immunology/blood
  • SARS-CoV-2/immunology
  • Female
  • Inflammation/immunology
  • *Progranulins/immunology
  • Male
  • Protein Isoforms/immunology
  • Interleukin-1/metabolism
  • Middle Aged
  • Signal Transduction
  • Aged
  • Tumor Necrosis Factor-alpha/metabolism
  • Monocytes/immunology/metabolism
  • Adult
Publication details
DOI: 10.1038/s41467-026-73316-5
Journal: Nat Commun
Number: 1
Work Type: Original
Location: UGMLC
Disease Area: PALI
Partner / Member: JLU, MPI-BN
Access-Number: 42204159
See publication on PubMed


chevron-down